UPI (MM)

MINNEAPOLIS, Feb. 27, 2015 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that it will participate in the 27th Annual ROTH Conference on Tuesday, March 10, 2015. Rob Kill, President and CEO, and Brett Reynolds, Chief Financial Officer, will present at 4:00 p.m. Pacific Time and meet with investors one on one at the conference at the Ritz Carlton in Laguna Niguel, CA.

Attendance at the conference is by invitation only. A live webcast of the presentation with accompanying slides will be broadcast via the Internet. Those interested in joining the webcast may access it through Uroplasty's website at www.uroplasty.com. An archived replay of the presentation will be available for 90 days following the event.

About Uroplasty
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a global medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Uroplasty's focus is the continued commercialization of its Urgent® PC Neuromodulation System, which Uroplasty believes is the only commercially available, FDA-cleared device that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). OAB is a chronic condition that affects approximately 42 million U.S. adults.  The symptoms include urinary urgency, frequency and urge incontinence.  Uroplasty also offers Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on Uroplasty and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/uroplasty-to-participate-in-the-27th-annual-roth-conference-300042614.html

SOURCE Uroplasty, Inc.